JP2002505672A - 水溶液中における保護されていないか又はｎ−末端システインで保護されたペプチドの固相での自然化学連結 - Google Patents
水溶液中における保護されていないか又はｎ−末端システインで保護されたペプチドの固相での自然化学連結Info
- Publication number
- JP2002505672A JP2002505672A JP50326799A JP50326799A JP2002505672A JP 2002505672 A JP2002505672 A JP 2002505672A JP 50326799 A JP50326799 A JP 50326799A JP 50326799 A JP50326799 A JP 50326799A JP 2002505672 A JP2002505672 A JP 2002505672A
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- solid phase
- terminal
- segment
- unprotected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 578
- 239000007790 solid phase Substances 0.000 title claims abstract description 248
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 85
- 239000007864 aqueous solution Substances 0.000 title claims abstract description 15
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 title claims description 76
- 235000018417 cysteine Nutrition 0.000 title claims description 61
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 title claims description 60
- 239000000126 substance Substances 0.000 title abstract description 57
- 238000000034 method Methods 0.000 claims abstract description 88
- 238000012544 monitoring process Methods 0.000 claims abstract description 6
- 210000004899 c-terminal region Anatomy 0.000 claims description 86
- 150000007970 thio esters Chemical class 0.000 claims description 60
- 238000006243 chemical reaction Methods 0.000 claims description 51
- 125000006239 protecting group Chemical group 0.000 claims description 49
- 229920001184 polypeptide Polymers 0.000 claims description 41
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims description 29
- 239000007787 solid Substances 0.000 claims description 27
- 239000002253 acid Substances 0.000 claims description 26
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 23
- 235000001014 amino acid Nutrition 0.000 claims description 21
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 230000027455 binding Effects 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000004202 carbamide Substances 0.000 claims description 12
- 238000010532 solid phase synthesis reaction Methods 0.000 claims description 12
- 125000000539 amino acid group Chemical group 0.000 claims description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 238000004949 mass spectrometry Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 239000012508 resin bead Substances 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims 2
- FXXACINHVKSMDR-UHFFFAOYSA-N acetyl bromide Chemical compound CC(Br)=O FXXACINHVKSMDR-UHFFFAOYSA-N 0.000 claims 1
- 239000003791 organic solvent mixture Substances 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 abstract description 16
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 abstract description 15
- 102000004169 proteins and genes Human genes 0.000 abstract description 15
- 108090000623 proteins and genes Proteins 0.000 abstract description 15
- 230000015572 biosynthetic process Effects 0.000 abstract description 13
- 230000002194 synthesizing effect Effects 0.000 abstract description 8
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 abstract description 6
- 229920005989 resin Polymers 0.000 description 107
- 239000011347 resin Substances 0.000 description 107
- 238000004128 high performance liquid chromatography Methods 0.000 description 37
- 239000000243 solution Substances 0.000 description 30
- 239000000047 product Substances 0.000 description 27
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 27
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 25
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- 238000005406 washing Methods 0.000 description 24
- QMHAHUAQAJVBIW-UHFFFAOYSA-N [methyl(sulfamoyl)amino]methane Chemical compound CN(C)S(N)(=O)=O QMHAHUAQAJVBIW-UHFFFAOYSA-N 0.000 description 23
- 238000003776 cleavage reaction Methods 0.000 description 23
- 230000007017 scission Effects 0.000 description 22
- 238000005859 coupling reaction Methods 0.000 description 21
- 230000008878 coupling Effects 0.000 description 20
- 238000010168 coupling process Methods 0.000 description 19
- 229960004198 guanidine Drugs 0.000 description 19
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 17
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 16
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 16
- 229930182817 methionine Natural products 0.000 description 16
- 238000000746 purification Methods 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 13
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 13
- 125000000524 functional group Chemical group 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 12
- 238000010586 diagram Methods 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- 239000000543 intermediate Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- -1 POROSTM Substances 0.000 description 9
- 238000009833 condensation Methods 0.000 description 9
- 230000005494 condensation Effects 0.000 description 9
- 238000001819 mass spectrum Methods 0.000 description 9
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 description 8
- 101800001415 Bri23 peptide Proteins 0.000 description 8
- 102400000107 C-terminal peptide Human genes 0.000 description 8
- 101800000655 C-terminal peptide Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 238000005520 cutting process Methods 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 238000010647 peptide synthesis reaction Methods 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000002457 bidirectional effect Effects 0.000 description 6
- CZGCBYXXDMGKNM-NSHDSACASA-N bis(2,2-dimethylpropyl) (2s)-2-aminopentanedioate Chemical compound CC(C)(C)COC(=O)CC[C@H](N)C(=O)OCC(C)(C)C CZGCBYXXDMGKNM-NSHDSACASA-N 0.000 description 6
- 239000006227 byproduct Substances 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- 239000012467 final product Substances 0.000 description 6
- 150000002576 ketones Chemical class 0.000 description 6
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 235000018977 lysine Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- 102100037611 Lysophospholipase Human genes 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 108010058864 Phospholipases A2 Proteins 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 4
- 235000003704 aspartic acid Nutrition 0.000 description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000007596 consolidation process Methods 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 4
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 4
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 230000006340 racemization Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000007086 side reaction Methods 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 150000003573 thiols Chemical group 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 235000019687 Lamb Nutrition 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 229940040102 levulinic acid Drugs 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 125000002653 sulfanylmethyl group Chemical group [H]SC([H])([H])[*] 0.000 description 3
- 150000003462 sulfoxides Chemical class 0.000 description 3
- NQRKYASMKDDGHT-UHFFFAOYSA-N (aminooxy)acetic acid Chemical compound NOCC(O)=O NQRKYASMKDDGHT-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000004568 cement Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 238000001869 matrix assisted laser desorption--ionisation mass spectrum Methods 0.000 description 2
- BRMYZIKAHFEUFJ-UHFFFAOYSA-L mercury diacetate Chemical compound CC(=O)O[Hg]OC(C)=O BRMYZIKAHFEUFJ-UHFFFAOYSA-L 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- AIZZGGDXFGAYMR-IBGZPJMESA-N (2r)-3-(9h-fluoren-9-ylmethylsulfanyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound C1=CC=C2C(CSC[C@H](NC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 AIZZGGDXFGAYMR-IBGZPJMESA-N 0.000 description 1
- HLCTYBOTPCIHTG-QMMMGPOBSA-N (2r)-3-(acetamidomethylsulfanyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(=O)NCSC[C@@H](C(O)=O)NC(=O)OC(C)(C)C HLCTYBOTPCIHTG-QMMMGPOBSA-N 0.000 description 1
- JYEVQYFWINBXJU-QFIPXVFZSA-N (2s)-6-(9h-fluoren-9-ylmethoxycarbonylamino)-2-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical class C1=CC=C2C(COC(=O)NCCCC[C@H](NC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 JYEVQYFWINBXJU-QFIPXVFZSA-N 0.000 description 1
- NQRKYASMKDDGHT-UHFFFAOYSA-M (aminooxy)acetate Chemical compound NOCC([O-])=O NQRKYASMKDDGHT-UHFFFAOYSA-M 0.000 description 1
- CTTUQCIBNSCQRH-UHFFFAOYSA-N 2,3,4-trimethylpentan-3-amine Chemical compound CC(C)C(C)(N)C(C)C CTTUQCIBNSCQRH-UHFFFAOYSA-N 0.000 description 1
- OQYBTXFHTQYWCZ-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(4-methylphenyl)methylsulfanyl]propanoic acid Chemical compound C1=CC(C)=CC=C1CSCC(C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 OQYBTXFHTQYWCZ-UHFFFAOYSA-N 0.000 description 1
- QBXODCKYUZNZCY-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]oxyacetic acid Chemical compound CC(C)(C)OC(=O)NOCC(O)=O QBXODCKYUZNZCY-UHFFFAOYSA-N 0.000 description 1
- VFJLNJOSBVVKLZ-UHFFFAOYSA-N 2-aminooxy-3-[(2-methylpropan-2-yl)oxy]-3-oxopropanoic acid Chemical class CC(C)(C)OC(=O)C(ON)C(O)=O VFJLNJOSBVVKLZ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- ZZOKVYOCRSMTSS-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl carbamate Chemical compound C1=CC=C2C(COC(=O)N)C3=CC=CC=C3C2=C1 ZZOKVYOCRSMTSS-UHFFFAOYSA-N 0.000 description 1
- 101150052147 ALLC gene Proteins 0.000 description 1
- 241001556567 Acanthamoeba polyphaga mimivirus Species 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- LVRCEUVOXCJYSV-UHFFFAOYSA-N CN(C)S(=O)=O Chemical compound CN(C)S(=O)=O LVRCEUVOXCJYSV-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010074105 Factor Va Proteins 0.000 description 1
- 239000012630 HPLC buffer Substances 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 102100034757 Thiol S-methyltransferase METTL7B Human genes 0.000 description 1
- 101710082490 Thiol S-methyltransferase METTL7B Proteins 0.000 description 1
- 241001061127 Thione Species 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- MNZMECMQTYGSOI-UHFFFAOYSA-N acetic acid;hydron;bromide Chemical compound Br.CC(O)=O MNZMECMQTYGSOI-UHFFFAOYSA-N 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 125000006242 amine protecting group Chemical group 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000005667 attractant Substances 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- KDPAWGWELVVRCH-UHFFFAOYSA-N bromoacetic acid Chemical class OC(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- DWYMPOCYEZONEA-UHFFFAOYSA-L fluoridophosphate Chemical compound [O-]P([O-])(F)=O DWYMPOCYEZONEA-UHFFFAOYSA-L 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000001698 laser desorption ionisation Methods 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- BQPIGGFYSBELGY-UHFFFAOYSA-N mercury(2+) Chemical compound [Hg+2] BQPIGGFYSBELGY-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- SBOJXQVPLKSXOG-UHFFFAOYSA-N o-amino-hydroxylamine Chemical compound NON SBOJXQVPLKSXOG-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 108010091748 peptide A Proteins 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 239000005373 porous glass Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
- C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
- C07K1/086—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents containing sulfur
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
- C07K1/023—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution using racemisation inhibiting agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
- C07K1/026—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4955397P | 1997-06-13 | 1997-06-13 | |
| US60/049,553 | 1997-06-13 | ||
| PCT/US1998/012278 WO1998056807A1 (en) | 1997-06-13 | 1998-06-12 | Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002505672A true JP2002505672A (ja) | 2002-02-19 |
| JP2002505672A5 JP2002505672A5 (enExample) | 2005-12-22 |
Family
ID=21960431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50326799A Ceased JP2002505672A (ja) | 1997-06-13 | 1998-06-12 | 水溶液中における保護されていないか又はｎ−末端システインで保護されたペプチドの固相での自然化学連結 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US6326468B1 (enExample) |
| EP (1) | EP1001968B1 (enExample) |
| JP (1) | JP2002505672A (enExample) |
| AT (2) | ATE354584T1 (enExample) |
| AU (1) | AU745094B2 (enExample) |
| CA (1) | CA2292724A1 (enExample) |
| DE (2) | DE69828287T2 (enExample) |
| ES (2) | ES2235336T3 (enExample) |
| WO (1) | WO1998056807A1 (enExample) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007046456A1 (ja) * | 2005-10-19 | 2007-04-26 | Chugai Seiyaku Kabushiki Kaisha | 新規水溶性プロドラッグを含有する、膵臓癌、卵巣癌または肝臓癌の予防または治療剤 |
| US7910593B2 (en) | 2004-04-09 | 2011-03-22 | Chugai Seiyaku Kabushiki Kaisha | Water-soluble prodrugs |
| US8022047B2 (en) | 2005-08-22 | 2011-09-20 | Chugai Seiyaku Kabushiki Kaisha | Combination anticancer agents |
| JP2014532075A (ja) * | 2011-10-17 | 2014-12-04 | サントル ナシオナル ドゥ ラ ルシェルシェサイアンティフィク（セエヌエールエス） | タンパク質の合成方法 |
| KR20210098466A (ko) * | 2018-11-30 | 2021-08-10 | 가부시키가이샤 도우사 고가쿠 겐큐쇼 | 펩티드 티오에스테르 및 펩티드의 신규 제조 방법 |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6184344B1 (en) * | 1995-05-04 | 2001-02-06 | The Scripps Research Institute | Synthesis of proteins by native chemical ligation |
| US6849428B1 (en) * | 1997-03-05 | 2005-02-01 | New England Biolabs, Inc. | Intein-mediated protein ligation of expressed proteins |
| ES2235336T3 (es) * | 1997-06-13 | 2005-07-01 | Gryphon Therapeutics, Inc. | Ligacion quimica nativa en fase solida de peptidos desprotegidos o protegidos en la cisteina n-terminal en solucion acuosa. |
| US6844161B2 (en) | 1997-09-04 | 2005-01-18 | Gryphon Therapeutics, Inc. | Modular protein libraries and methods of preparation |
| AUPP589598A0 (en) | 1998-09-14 | 1998-10-08 | University Of Queensland, The | Novel peptides |
| US7001745B1 (en) * | 1998-09-30 | 2006-02-21 | New England Biolabs, Inc. | Intein mediated peptide ligation |
| CA2372164A1 (en) * | 1999-03-11 | 2000-09-14 | Gerd G. Kochendoerfer | Chemical synthesis and use of soluble membrane protein receptor domains |
| SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| US20020155455A1 (en) * | 2000-08-11 | 2002-10-24 | Invitrogen Corporation | Highly homogeneous molecular markers for electrophoresis |
| US20040014082A1 (en) * | 2000-08-11 | 2004-01-22 | Invitrogen Corporation | Highly homogeneous molecular markers for electrophoresis |
| JP2004507557A (ja) * | 2000-09-01 | 2004-03-11 | グリフォン セラピューティクス，インコーポレーテッド | 求核物質に対して安定なチオエステル生成化合物、製造および使用の方法 |
| CA2435394C (en) * | 2001-01-22 | 2018-01-09 | Sangamo Biosciences, Inc. | Modified zinc finger binding proteins |
| JP4408628B2 (ja) * | 2001-03-09 | 2010-02-03 | ボストン プローブス，インコーポレイテッド | 組み合わせオリゴマーならびにそれらの調製のためのライブラリーに適する、方法、キット、および組成物 |
| GB0113657D0 (en) * | 2001-06-05 | 2001-07-25 | Geneprot Inc | Improved native chemical ligation with three or more components |
| ES2411007T3 (es) | 2001-10-10 | 2013-07-04 | Novo Nordisk A/S | Remodelación y glicoconjugación de péptidos |
| US7781488B2 (en) * | 2002-06-10 | 2010-08-24 | Amylin Pharmaceuticals, Inc. | Post-cleavage sulfur deprotection for convergent protein synthesis by chemical ligation |
| JP2005531616A (ja) * | 2002-06-29 | 2005-10-20 | アクヴァノヴァ・ジャーマン・ソリュービリセイト・テクノロジーズ・（アーゲーテー）・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | イソフラボン濃縮物およびその製造法 |
| US7166574B2 (en) * | 2002-08-20 | 2007-01-23 | Biosurface Engineering Technologies, Inc. | Synthetic heparin-binding growth factor analogs |
| US8227411B2 (en) | 2002-08-20 | 2012-07-24 | BioSurface Engineering Technologies, Incle | FGF growth factor analogs |
| US7598224B2 (en) | 2002-08-20 | 2009-10-06 | Biosurface Engineering Technologies, Inc. | Dual chain synthetic heparin-binding growth factor analogs |
| AU2003300859A1 (en) * | 2002-12-11 | 2004-06-30 | New England Biolabs, Inc. | Carrier-ligand fusions and uses thereof |
| WO2004061094A1 (en) | 2002-12-30 | 2004-07-22 | Gryphon Therapeutics, Inc. | Water-soluble thioester and selenoester compounds and methods for making and using the same |
| CA2522345A1 (en) | 2003-04-09 | 2004-11-18 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| PT1624891E (pt) * | 2003-05-06 | 2010-01-05 | Syntonix Pharmaceuticals Inc | Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia |
| US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| EP1631597A4 (en) * | 2003-05-22 | 2007-07-11 | Gryphon Therapeutics Inc | SOLID PHASE CHEMICAL LIGATION CARRIED OUT WITH A MOBILE BONDING AGENT |
| US7414028B1 (en) | 2004-02-04 | 2008-08-19 | Biosurface Engineering Technologies, Inc. | Growth factor analogs |
| US20060024347A1 (en) * | 2004-02-10 | 2006-02-02 | Biosurface Engineering Technologies, Inc. | Bioactive peptide coatings |
| US7671012B2 (en) | 2004-02-10 | 2010-03-02 | Biosurface Engineering Technologies, Inc. | Formulations and methods for delivery of growth factor analogs |
| US20080227696A1 (en) | 2005-02-22 | 2008-09-18 | Biosurface Engineering Technologies, Inc. | Single branch heparin-binding growth factor analogs |
| US7528105B1 (en) | 2004-02-10 | 2009-05-05 | Biosurface Engineering Technologies | Heterodimeric chain synthetic heparin-binding growth factor analogs |
| DE602005023714D1 (de) | 2004-02-20 | 2010-11-04 | Biosurface Eng Tech Inc | Positiver modulator des knochenmorphogenetisches protein-2 (bmp-2) |
| EP1749022A2 (en) * | 2004-05-24 | 2007-02-07 | Rigel Pharmaceuticals, Inc. | Methods for cyclizing synthetic polymers |
| CN102343084A (zh) | 2005-03-31 | 2012-02-08 | 安米林药品公司 | 用于治疗精神病和精神障碍的胰淀素和胰淀素激动剂 |
| US7674881B2 (en) * | 2005-10-07 | 2010-03-09 | The University Of Chicago | Convergent synthesis of proteins by kinetically controlled ligation |
| US7820172B1 (en) | 2006-06-01 | 2010-10-26 | Biosurface Engineering Technologies, Inc. | Laminin-derived multi-domain peptides |
| EP2046350A4 (en) | 2006-06-22 | 2011-09-14 | Biosurface Eng Tech Inc | COMPOSITION AND METHOD FOR DELIVERING AMPLIFIER / CO-ACTIVATOR OF BMP-2 TO ENHANCE OSTEOGENESIS |
| EP2120985B1 (en) | 2007-02-05 | 2012-06-27 | Amylin Pharmaceuticals, Inc. | FN-38 peptides for use in the treatment of psychotic and anxiety disorders |
| WO2009032133A2 (en) * | 2007-08-28 | 2009-03-12 | Ipsen Pharma S.A.S. | Methods and intermediates for chemical synthesis of polypeptides and proteins |
| US8927485B2 (en) * | 2010-02-18 | 2015-01-06 | Advanced Proteome Therapeutics Inc. | Site-specific modification of proteins through chemical modification enabling protein conjugates, protein dimer formation, and stapled peptides |
| ES2563091T3 (es) | 2010-09-28 | 2016-03-10 | Amylin Pharmaceuticals, Llc | Polipéptidos modificados genéticamente que tienen duración de acción potenciada |
| PT2621519T (pt) | 2010-09-28 | 2017-10-04 | Aegerion Pharmaceuticals Inc | Polipéptido de fusão de leptina-abd com duração de ação melhorada |
| CN103957926B (zh) | 2011-07-08 | 2018-07-03 | 安米林药品有限责任公司 | 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽 |
| JP6006309B2 (ja) | 2011-07-08 | 2016-10-12 | アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc | 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド |
| US9545449B2 (en) | 2012-05-11 | 2017-01-17 | Advanced Proteone Therapeutics Inc. | Site-specific labeling and targeted delivery of proteins for the treatment of cancer |
| US9498538B2 (en) | 2012-05-21 | 2016-11-22 | Massachusetts Institute Of Technology | Translocation of non-natural chemical entities through anthrax protective antigen pore |
| WO2014144549A1 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Factor ix polypeptide formulations |
| WO2017151939A1 (en) * | 2016-03-02 | 2017-09-08 | The Brigham And Women's Hospital, Inc. | Use of pla2g5-deficient suppressive macrophages in suppression of inflammation |
| US11214592B2 (en) * | 2017-03-02 | 2022-01-04 | Glytech, Inc. | Production method for amino-acid polymer |
| CA3114571A1 (en) | 2018-10-01 | 2020-04-09 | Universite De Geneve | Methods for producing a plurality of polypeptide variants suitable for biological analysis |
| CA3157359A1 (en) | 2019-10-10 | 2021-04-15 | 1859, Inc. | Methods and systems for microfluidic screening |
| JP7289799B2 (ja) * | 2019-10-23 | 2023-06-12 | 煙台邁百瑞国際生物医薬股▲ふん▼有限公司 | オリゴペプチドリンカー中間体及びその製造方法 |
| WO2022266467A2 (en) | 2021-06-17 | 2022-12-22 | Dana-Farber Cancer Institute, Inc. | Recombinant histone polypeptide and uses thereof |
| WO2024146707A1 (en) | 2023-01-06 | 2024-07-11 | Université De Genève | Variant ligand conjugates for payload delivery |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5064940A (en) * | 1988-05-11 | 1991-11-12 | Protein Technologies, Inc. | Premixed dry reagent containing a protected amino acid and an activating agent for use in solid phase protein synthesis |
| US5101059A (en) * | 1989-12-05 | 1992-03-31 | Research Corporation Technologies, Inc. | Amino acid protecting groups |
| MX9708500A (es) * | 1995-05-04 | 1998-02-28 | Scripps Research Inst | Sintesis de proteinas mediante ligacion quimica nativa. |
| WO1998028434A1 (en) | 1996-12-24 | 1998-07-02 | The Scripps Research Institute | General chemical ligation |
| ES2235336T3 (es) * | 1997-06-13 | 2005-07-01 | Gryphon Therapeutics, Inc. | Ligacion quimica nativa en fase solida de peptidos desprotegidos o protegidos en la cisteina n-terminal en solucion acuosa. |
| US6329468B1 (en) * | 2000-01-21 | 2001-12-11 | Bostik Findley, Inc. | Hot melt adhesive based on semicrystalline flexible polyolefins |
-
1998
- 1998-06-12 ES ES98929035T patent/ES2235336T3/es not_active Expired - Lifetime
- 1998-06-12 WO PCT/US1998/012278 patent/WO1998056807A1/en not_active Ceased
- 1998-06-12 AU AU80695/98A patent/AU745094B2/en not_active Ceased
- 1998-06-12 US US09/097,094 patent/US6326468B1/en not_active Expired - Fee Related
- 1998-06-12 AT AT04029270T patent/ATE354584T1/de not_active IP Right Cessation
- 1998-06-12 DE DE69828287T patent/DE69828287T2/de not_active Expired - Fee Related
- 1998-06-12 DE DE69837170T patent/DE69837170T2/de not_active Expired - Fee Related
- 1998-06-12 ES ES04029270T patent/ES2282788T3/es not_active Expired - Lifetime
- 1998-06-12 EP EP98929035A patent/EP1001968B1/en not_active Expired - Lifetime
- 1998-06-12 JP JP50326799A patent/JP2002505672A/ja not_active Ceased
- 1998-06-12 CA CA002292724A patent/CA2292724A1/en not_active Abandoned
- 1998-06-12 AT AT98929035T patent/ATE285415T1/de not_active IP Right Cessation
-
2001
- 2001-11-15 US US09/987,655 patent/US7094871B2/en not_active Expired - Fee Related
- 2001-11-15 US US09/987,675 patent/US7030217B2/en not_active Expired - Fee Related
-
2005
- 2005-05-03 US US11/119,831 patent/US20050209440A1/en not_active Abandoned
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7910593B2 (en) | 2004-04-09 | 2011-03-22 | Chugai Seiyaku Kabushiki Kaisha | Water-soluble prodrugs |
| US8022047B2 (en) | 2005-08-22 | 2011-09-20 | Chugai Seiyaku Kabushiki Kaisha | Combination anticancer agents |
| WO2007046456A1 (ja) * | 2005-10-19 | 2007-04-26 | Chugai Seiyaku Kabushiki Kaisha | 新規水溶性プロドラッグを含有する、膵臓癌、卵巣癌または肝臓癌の予防または治療剤 |
| JP2014532075A (ja) * | 2011-10-17 | 2014-12-04 | サントル ナシオナル ドゥ ラ ルシェルシェサイアンティフィク（セエヌエールエス） | タンパク質の合成方法 |
| KR20210098466A (ko) * | 2018-11-30 | 2021-08-10 | 가부시키가이샤 도우사 고가쿠 겐큐쇼 | 펩티드 티오에스테르 및 펩티드의 신규 제조 방법 |
| KR102769851B1 (ko) * | 2018-11-30 | 2025-02-20 | 가부시키가이샤 도우사 고가쿠 겐큐쇼 | 펩티드 티오에스테르 및 펩티드의 신규 제조 방법 |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2235336T3 (es) | 2005-07-01 |
| EP1001968B1 (en) | 2004-12-22 |
| US20050209440A1 (en) | 2005-09-22 |
| ES2282788T3 (es) | 2007-10-16 |
| ATE285415T1 (de) | 2005-01-15 |
| WO1998056807A1 (en) | 1998-12-17 |
| CA2292724A1 (en) | 1998-12-17 |
| DE69828287T2 (de) | 2005-12-15 |
| ATE354584T1 (de) | 2007-03-15 |
| US7030217B2 (en) | 2006-04-18 |
| EP1001968A1 (en) | 2000-05-24 |
| US20020169282A1 (en) | 2002-11-14 |
| DE69837170D1 (de) | 2007-04-05 |
| US6326468B1 (en) | 2001-12-04 |
| DE69837170T2 (de) | 2007-11-22 |
| US20020132975A1 (en) | 2002-09-19 |
| US7094871B2 (en) | 2006-08-22 |
| DE69828287D1 (de) | 2005-01-27 |
| AU8069598A (en) | 1998-12-30 |
| AU745094B2 (en) | 2002-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002505672A (ja) | 水溶液中における保護されていないか又はｎ−末端システインで保護されたペプチドの固相での自然化学連結 | |
| EP1392718B1 (en) | Improved native chemical ligation with three or more components | |
| US4786684A (en) | Benzylthioether-linked solid support-bound thiol compounds and method for peptide synthesis | |
| CZ80399A3 (cs) | Způsob výroby peptidů | |
| JP2001507027A (ja) | 一般的化学結合 | |
| JP4399627B2 (ja) | ３つまたはそれ以上の成分による化学ペプチド連結 | |
| JPH0632790A (ja) | ビオチン導入試薬およびそれを用いる合成ペプチド精製法 | |
| RU2182155C2 (ru) | Получение очищенных (поли)пептидов | |
| EP1518862B1 (en) | Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution | |
| JP2005529188A (ja) | オリゴペプチドの化学連結における酸性ｃ末端アミノ酸についてのカルボキシ保護ストラテジー | |
| JP2018145151A (ja) | 多機能型ペプチドプローブ及びこれを用いた標的分子の選択的濃縮法 | |
| JP2010537984A (ja) | ポリペプチドおよび蛋白質の化学合成のための方法および中間体 | |
| JP2777193B2 (ja) | ペプチドの製造方法 | |
| MORELL et al. | Cleavage of aspartyl β‐phenacyl esters by selenophenol under neutral conditions | |
| AU2002319850A1 (en) | Improved native chemical ligation with three or more components | |
| US20050096456A1 (en) | Compounds comprising pseudo-amino acids | |
| WO2007043615A1 (ja) | ペプチドエステル試薬、およびそのライゲーションまたはチオエステル化合物の製造のための使用 | |
| Bianchi et al. | Engineering and chemical synthesis of the HCV protease transmembrane protein cofactor NS4A | |
| BURTON | PEPTIDE SEMISYNTHESIS WITH UNBLOCKED BETA (PORCINE)-MSH | |
| WO2009140186A1 (en) | Methods of preparing peptide derivatives | |
| AU2002363612A1 (en) | Extended native chemical ligation of three or more peptide fragments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050607 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050607 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080304 |
|
| A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20080722 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080930 |